ALLO — Allogene Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $336.76m
- $44.28m
- $0.02m
Annual cashflow statement for Allogene Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -250 | -257 | -333 | -327 | -258 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 73.6 | 93.8 | 94.1 | 90.6 | 68.5 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 53.9 | -32.1 | 3.71 | -15.3 | -24.8 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -115 | -185 | -221 | -238 | -200 |
| Capital Expenditures | -66 | -21.4 | -5.19 | -1.52 | -0.694 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -439 | 185 | 111 | 165 | 76.4 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -505 | 164 | 106 | 163 | 75.7 |
| Financing Cash Flow Items | — | — | — | — | 2.28 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 634 | 12 | 2.95 | 95.7 | 117 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 13.4 | -9.19 | -111 | 21.3 | -7.94 |